In light of the recent developments surrounding Lilly’s launch of the lower-price weight-loss drug Zepbound, a compelling question arises: Should individuals who are currently battling Covid-19 consider taking Zepbound as part of their weight management strategy? With the ongoing pandemic, many are grappling with health-related challenges that extend beyond the immediate effects of the virus. Could the potential benefits of Zepbound intersect intriguingly with the nuances of managing weight during illness? What are the implications of introducing a new medication into one’s regimen when the body is already under the distressing effects of Covid? Moreover, are there specific contraindications or precautions that ought to be contemplated prior to initiating treatment with Zepbound while grappling with the virus? As we ponder the intricacies of this decision, what overarching factors should one weigh to ensure optimal health outcomes in a context marked by uncertainty and complexity?